Linesta (Linagliptin)

Linagliptin is an oral antidiabetic medication from the DPP‑4 inhibitor class, used to improve glycemic control in adults with type 2 diabetes. By blocking the DPP‑4 enzyme, linagliptin increases levels of incretin hormones that stimulate insulin release and reduce glucagon secretion when blood glucose levels are elevated. Its standout feature is its primarily biliary excretion, allowing use across all stages of renal impairment without dose adjustment. Linagliptin is weight‑neutral, has a low risk of hypoglycemia, and is commonly used as monotherapy or in combination with metformin, SGLT2 inhibitors, sulfonylureas, or insulin. It is recommended in diabetes guidelines as an add‑on therapy for patients needing improved HbA1c control with minimal side‑effect burden.